Non-Current Assets
Operating Lease Right-of-Use Assets in Other Assets
Neurocrine Biosciences Operating Lease Right-of-Use Assets in Other Assets decreased by 1.8% to $447.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 11.0%, from $502.20M to $447.10M. Over 5 years (FY 2020 to FY 2025), Operating Lease Right-of-Use Assets in Other Assets shows an upward trend with a 40.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2018
Last reportedQ1 2026May 5, 2026
Metric ID:
operating_lease_rou_assets_in_otherHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $100.30M | $97.90M | $97.20M | $94.70M | $92.20M | $89.60M | $87.00M | $84.40M | $83.50M | $80.80M | $276.50M | $270.80M | $262.90M | $257.30M | $509.40M | $502.20M | $492.30M | $468.90M | $455.40M | $447.10M |
| QoQ Change | — | -2.4% | -0.7% | -2.6% | -2.6% | -2.8% | -2.9% | -3.0% | -1.1% | -3.2% | +242.2% | -2.1% | -2.9% | -2.1% | +98.0% | -1.4% | -2.0% | -4.8% | -2.9% | -1.8% |
| YoY Change | — | — | — | — | -8.1% | -8.5% | -10.5% | -10.9% | -9.4% | -9.8% | +217.8% | +220.9% | +214.9% | +218.4% | +84.2% | +85.5% | +87.3% | +82.2% | -10.6% | -11.0% |
Range$80.80M – $509.40M
CAGR+37.0%
Avg YoY Growth+70.8%
Median YoY Growth+37.1%
Current Streak5 quarters decline
Operating Lease Right-of-Use Assets in Other Assets at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating lease right-of-use assets in other assets?
- Neurocrine Biosciences (NBIX) reported operating lease right-of-use assets in other assets of $447.10M in Q1 2026.
- How has Neurocrine Biosciences's operating lease right-of-use assets in other assets changed year-over-year?
- Neurocrine Biosciences's operating lease right-of-use assets in other assets decreased by 11.0% year-over-year, from $502.20M to $447.10M.
- What is the long-term trend for Neurocrine Biosciences's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's operating lease right-of-use assets in other assets has grown at a 40.6% compound annual growth rate (CAGR), from $82.80M to $455.40M.